Immunovia Completes Acquisition of Blood Samples for Test Validation
Immunovia Completes Acquisition of Blood Samples for Test Validation
Immunovia, the innovative pancreatic cancer diagnostics company, has successfully acquired all necessary blood samples to clinically validate its next-generation test for pancreatic cancer. This significant achievement marks a crucial milestone in the company's journey toward completing a comprehensive clinical validation study.
Clinical Validation Study Overview
The primary goal of this extensive study is to affirm the sensitivity and specificity demonstrated in earlier model-development studies. It will employ a case-control approach to evaluate how accurately the new test distinguishes between blood samples from individuals diagnosed with early-stage pancreatic cancer and those who do not have the disease.
Blood Sample Collection Efforts
Immunovia successfully secured over 1,000 blood samples, with more than 200 collected from patients specifically diagnosed with stage 1 and stage 2 pancreatic cancer. Additionally, it gathered over 800 blood samples from high-risk individuals who do not currently have cancer. This study is set to be one of the largest validations of a pancreatic cancer biomarker test to date.
Collaboration with Leading Experts
The successful collection of samples involved leveraging established relationships with prominent researchers across pancreatic cancer centers in various regions. Notable contributors included Dr. Randall Brand from the University of Pittsburgh, Dr. Rosie Sears from Oregon Health and Science University, and Dr. Salvatore Paiella from the University of Verona.
Partnership with the PRECEDE Consortium
In another progressive step, this study represents Immunovia's inaugural collaboration with the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an esteemed international group of experts. Led by Dr. Diane Simeone, the consortium collaborates intensively to enhance early detection of the disease. They provided nearly 500 samples from ongoing studies targeting individuals at high risk due to hereditary factors.
Importance of Early Detection
"Securing all samples required for clinical validation marks a momentous step in our mission to provide early pancreatic cancer detection to high-risk individuals," says Jeff Borcherding, CEO and President of Immunovia. He emphasized the importance of this study in facilitating early cancer intervention, which could significantly improve patient outcomes.
Future Plans for the Test
Immunovia anticipates completing the clinical validation study, allowing it to introduce the next-generation test aimed at early pancreatic cancer detection in high-risk populations. As previously indicated, the company expects to finalize this study by the end of 2024, paving the way for a launch in 2025.
About Immunovia
Immunovia AB is committed to improving survival rates for patients diagnosed with pancreatic cancer through early detection. The company prioritizes developing and commercializing straightforward blood tests that identify proteins and antibodies indicative of pancreatic cancer risk.
Building strong collaborations with healthcare providers, leading experts, and patient advocacy groups, Immunovia aims to ensure that its diagnostic tests become accessible to those facing elevated pancreatic cancer risks. It is critical to note that the USA remains the world's largest market for pancreatic cancer detection.
The company estimates that approximately 1.8 million individuals in the USA are at a high risk for pancreatic cancer and could significantly benefit from annual surveillance testing.
Contact Information
For further inquiries, individuals can reach out to:
Jeff Borcherding
CEO and President
Karin Almqvist Liwendahl
Chief Financial Officer
+46 709 11 56 08
Frequently Asked Questions
What is the aim of the clinical validation study?
The primary aim is to confirm the sensitivity and specificity of Immunovia's next-generation pancreatic cancer test and evaluate its accuracy in distinguishing between affected and unaffected individuals.
How many blood samples did Immunovia acquire?
Immunovia secured over 1,000 blood samples, with a significant portion coming from patients diagnosed at earlier stages and high-risk individuals without current cancer diagnoses.
What is the role of the PRECEDE Consortium?
The PRECEDE Consortium provides access to samples and collaboration aimed at enhancing early detection strategies for pancreatic cancer globally through shared expertise.
What does early detection mean for pancreatic cancer patients?
Early detection significantly improves the chances of successful intervention and treatment, which can help increase survival rates for those diagnosed with pancreatic cancer.
When does Immunovia plan to launch its new test?
Immunovia plans to complete its clinical validation study by the end of 2024, with the aim of launching the next-generation test for early detection of pancreatic cancer in 2025.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Tony Fadell Champions Plumerai's Tiny AI for Smart Homes
- BizClik Media Unveils Latest Issues of Key Industry Magazines
- Comstock's Strategic Expansion Through GenMat Acquisition
- Mullen Automotive Aims for $75M Revenue Amid Cost-Cutting Efforts
- Townsquare Media Partners with SummitMedia for Advertising Growth
- Wells Fargo Sees Positive EPS Growth for Canadian National Railway
- Ambow Education Secures $1.3 Million Licensing Deal for HybriU
- Hooker Furnishings Partners with Margaritaville for Home Collection
- Future Growth of Health Information Exchange Market Explored
- Comstock's Strategic Acquisition of Quantum Generative Materials
Recent Articles
- Morgan Stanley's Downgrade: Impacts on Garmin's Future Stocks
- DuPont Faces Downgrade Despite Recent Growth and Expansion
- Barclays Adjusts Rating on Intapp Amid Growth Concerns
- Goldman Sachs Adjusts US Recession Outlook to 15% Amid Jobs Surge
- RBI Urges Banks to Limit Short Selling as Rupee Dips
- Walmart's Mysterious Blank Book on Kamala Harris Sparks Debate
- Mark Zuckerberg Turns Porsche Into Custom Minivan for Priscilla
- Deka Immobilien and BuildingMinds Unite for Carbon Reduction
- Newmark Appoints Marcus Lütgering as Germany Country Head
- Namibia and Elon Musk: Pioneering a Green Hydrogen Future
- OptiGroup Expands Reach with Acquisition of Døvigen AS
- Avery Dennison Corporation: Strong Earnings Forecast and Growth
- Citi Highlights Celldex's Promising Future in Drug Development
- Global Debt Challenges Impose Harsh Reality on Developing Nations
- Goldman Sachs Revises S&P 500 Outlook for Future Earnings Growth
- Market Dynamics Shift: India's Decline and China's Rise
- SUI Meme Token $HIPPO Launches Charity Initiative for Zoos
- Projected Growth of Nail Care Products Market to USD 34.9 Billion
- One Trading Strengthens Leadership With New Sales Head
- Tornator Oyj Explores Sustainable Green Note Issuance
- Danske Bank's Share Buy-Back Program Overview and Insights
- Transforming Indonesian Healthcare: Philips and Siloam Pact
- Understanding Prepayments and Their Impact on Realkredit Danmark
- Paysafe and GiG Forge Partnership for Enhanced iGaming Payments
- Lenzing and TreeToTextile Collaborate on Sustainable Fibers
- Lithium Africa Resources Strengthens Leadership with New Board Members
- Leopard Imaging Unveils ASA Cameras with BMW at AutoSens 2024
- Newmark Group Welcomes Marcus Lütgering as Germany's Head
- Decelera Ventures: A Unique Approach to Startup Growth
- Jacques Villeneuve Partners with CYPFER for Enhanced Cybersecurity
- Deka Immobilien Collaborates with BuildingMinds to Enhance ESG Efforts
- Lithium Africa Resources Corp. Expands Board with New Leaders
- Innovative Collaboration Between Lenzing and TreeToTextile
- Barclays Downgrades DS Smith Amid Merger Developments
- KeyBanc Adjusts SITE Centers Rating Amid Strategic Shift
- Curbline Properties Shows Promising Growth in Retail Sector
- Japan's Prime Minister Stresses Stability on Investment Tax Policy
- Exploring Promising Micro-Cap Stocks with High Potential
- Current Trends Impacting Oil Prices Amid Market Uncertainty
- AWS CEO Matt Garman Shares Insights on Generative AI's Evolution
- Elon Musk's X Faces Delays in Brazil Due to Banking Error
- Investors Spark Optimism as Major Stocks See Gains
- Explore Hisense's Premium ULED MiniLED TVs with Exclusive Offers
- Clover Health's Growth Prospects Spark UBS Interest in Stock
- Evotec Faces Downgrade: Analyst Perspective and Financial Outlook
- Market Movements: CPI Data and Earnings Reports in Focus
- FTSE 100 Experiences Initial Gains Amid Precious Metal Struggles
- Shell's Q3 2024 Expectations Enhanced by Upstream & Gas Volumes
- European Stock Market Update: Real Estate and Utilities Struggle
- Insights into Nykredit Realkredit A/S Prepayment Data Overview